Skip to main content

BHP researchers find new approach to detect meningitis and encephalitis

New research led by Aston University’s Dr Ghaniah Hassan-Smith has found a new technique to diagnose infections of the central nervous system, such as meningitis and encephalitis, which can be difficult to determine using conventional methods.

The method developed by Dr Hassan-Smith, clinical senior lecturer at Aston Medical School, and honorary consultant neurologist at University Hospitals Birmingham (UHB) and her BHP collaborators, is based on metagenomic sequencing – an existing and extremely sensitive genetic test – combined with a new and unique computational ‘filtering’ system to identify likely disease-causing bacteria and viruses from the complex information generated.

The cross-BHP research team included Dr Zaki Hassan Smith, clinical associate professor at Aston Medical School and consultant endocrinologist at UHB, and collaborators at the University of Birmingham – Professor Nicholas Loman, director of the Institute of Microbiology and Infection, Dr Joshua Quick, UKRI Future Leaders and Dr Nicola Cumley, clinical scientist.

Central nervous system infections can be serious and require rapid diagnosis and treatment. Usually, such infections are diagnosed by taking cerebrospinal fluid by lumbar puncture and combining knowledge of the patient’s symptoms with laboratory tests such as microscopy, microorganism culture and targeted polymerase chain reaction (PCR) tests for particular organisms. This requires the medical team to have some knowledge of what they are looking for.

In a substantial proportion of patients with a suspected central nervous system infection (over 50% in some settings, such as intensive care), no causative pathogenic organism is identified. This may be because the pathogen is unexpected, present only in small amounts, or because antibiotics or antiviral treatment have already been started.

Rather than testing for individual pathogens, metagenomic sequencing analyses all the genetic material present in a sample, takes out all the unnecessary genomic data and identifies DNA and RNA and which microorganisms it is likely to have come from. This means medical staff can look for many different bacteria, viruses and other microorganisms simultaneously, including unusual or unexpected pathogens. This is particularly relevant for central nervous system infections, where there can be major diagnostic challenges.

The researchers tested cerebrospinal fluid samples from patients with central nervous system infections, sourced from UHB, and compared them with non-infectious neurological control samples.

Samples can also be contaminated with other microorganisms, for example those found on skin or in laboratory reagents. This can lead to signals which appear disproportionately important. Dr Ghaniah Hassan-Smith and the team developed a series of filters to remove this ‘background noise’ based on bioinformatics. This is a technique that uses computational methods to understand biological data, in this case, the DNA and RNA signals from the fluid samples.

The filters are able to separate potentially meaningful pathogen signals from this background noise and so determine what the infectious agent is. The method brings together several pieces of sequencing information rather than relying on a single result.

Dr Ghaniah Hassan-Smith said: “Central nervous system infections such as meningitis and encephalitis can be extremely serious, but in many patients we never identify the organism responsible. Conventional tests are very good at finding the pathogens we suspect, but metagenomic sequencing gives us the exciting possibility of looking much more broadly, including for unusual or unexpected causes of infection.

“The difficulty is that looking for everything also means finding a lot of noise. Not every microbial signal detected in a sample represents a genuine infection, so interpreting these very complex datasets is one of the major challenges in bringing metagenomic sequencing into clinical practice.

“This isn’t intended to replace conventional microbiology. Rather, we hope the work contributes to developing more standardised ways of interpreting metagenomic sequencing and ultimately helps move this powerful technology closer to routine clinical practice.”

To read the full paper, ‘Pathogen detection in central nervous system infections: moving metagenomic sequencing closer to clinical practice’ in BMC Infectious Diseases, visit https://link.springer.com/article/10.1186/s12879-026-13276-9.

Birmingham expert chairs Independent Commission on safe AI adoption in healthcare

A Birmingham clinical academic has co-chaired a new report setting out how the NHS can adopt AI innovations while maintaining public trust and patient safety.

Professor Alastair Denniston of BHP founder-member the University of Birmingham has chaired the National Commission into the Regulation of AI in Healthcare which has published its recommendations on how the UK can strengthen the regulation of AI in healthcare – ensuring it remains safe, keeps pace with innovation, and continues to earn people’s trust.

AI is already used in the NHS to spot serious health problems early, for example strokes and skin cancers, and to free up clinicians’ time through voice-enabled technologies. The Commission’s recommendations aim to help more patients benefit safely and quickly, by supporting the UK to become the best place for innovators to build and safely test AI, the best place for healthcare professionals to use it and – most importantly – the best place for patients to engage with it in their care.

Professor Denniston, who Chairs the National Commission into the Regulation of AI in Healthcare, said: “We innovate because we believe tomorrow’s healthcare can be better than today’s. But any new innovation – including AI – needs to earn its place and earn our trust. These technologies need to show that they are safe, effective and bring benefits to patients, staff and the wider NHS, without leaving people behind.

“Over the past year we have heard from more than 12,000 people, including patients, carers, clinicians and the technologists building AI tools. One message came through clearly: people are open to AI improving their care, but only if it is safe, overseen by humans, and if they know when it is being used. These recommendations are designed to make that trust possible, so that the UK can lead the world not just in developing AI for healthcare, but in showing how it can be regulated and used responsibly.”

Among the key recommendations in the report, the Commission proposes a pathway for faster access to safe and effective AI.

The Commission recommends that the MHRA introduce staged authorisations for new AI models, similar to ‘L-plates’ for learner drivers. New models would be deployed under close supervision and tight guardrails, allowing them to demonstrate real-world safety and performance before being granted fuller authorisation. This staged approach is designed to give UK patients world-first access to promising new models, while ensuring risk is carefully controlled at every step.

Other recommendations include:

  • Continuous, real-world monitoring throughout a device’s lifecycle. Rather than a single, point-in-time approval, the Commission recommends that AI-enabled medical devices should be subject to continuous, real-world monitoring throughout their working life;
  • Public access to safety information. The Commission also recommends that members of the public should be able to easily search for information about the safety of specific AI-enabled medical devices, including any adverse incidents; and
  • Tougher powers to protect patients. The Commission recommends stronger powers for the MHRA, including enhanced enforcement powers, to ensure that where AI systems fall short of the standards patients expect, the regulator can act decisively.

Professor Henrietta Hughes, NHS General Practitioner, Deputy Chair of the National Commission and Patient Safety Commissioner for England, said: “Patients have told us that to trust AI is safe, they want to know when it’s used, that it supports rather than replaces clinicians, and that there is clear accountability if things go wrong. That’s exactly what our recommendations deliver.

“Putting people before technology to improve care and give clinicians more time to meet patients’ needs. That’s how we can keep people safe and build the health system’s confidence to embrace AI’s full potential.”

Lawrence Tallon, the MHRA’s Chief Executive said: “I welcome this authoritative and independent report which sets out in more detail than ever before how we should best regulate AI in healthcare.

“We have heard clearly about the opportunities of AI to speed up and improve care, and to release more of clinicians’ time for the essentially human aspects of their work with patients.

“We will only realise those opportunities if we have a modern, dynamic regulatory framework that accelerates safe adoption, protects patients and commands public and professional confidence. I am so grateful to the many people who contributed to this expert Commission to set out the roadmap ahead.”

The independent Commission was established by the Medicines and Healthcare products Regulatory Agency (MHRA) in September 2025 and includes diverse expertise across health, regulation and AI, including international contributors from around the world including the USA and Singapore.

The Commission gathered evidence from more than 12,000 people over the course of a year, including patients, the public, clinicians, healthcare leaders, industry and technology developers, making it the largest engagement of its kind ever undertaken in the UK on the regulation of healthcare technology. Additional in-depth deliberative research by research partner the Health Foundation with members of the UK public, published today, provided detailed insight into the UK public’s priorities and expectations for the regulation of AI in healthcare.

Taken together, that engagement found broad public support for AI in healthcare, with clear conditions: strong safety standards, meaningful human oversight, and transparency about when and how AI is being used in someone’s care. The Commission’s recommendations respond directly to these views.

Aston University’s health researchers to help guide redesign of Birmingham and Solihull’s NHS

Aston University is partnering with fellow BHP members Birmingham Community Healthcare NHS Foundation Trust (BCHC)  to build better joined-up health and care services in local neighbourhoods across Birmingham and Solihull.

This new approach aligns with the government’s 10-year health plan to create a Neighbourhood Health Service by moving care out of large hospitals and closer to people’s doorsteps, shifting focus towards preventing illness and moving from analogue systems to more efficient digital technology.

The three-year Knowledge Transfer Partnership (KTP) project will develop England’s first comprehensive system for monitoring how these changes impact patients and staff. It will provide critical metrics on people’s health, their experiences of care, and the well-being of NHS staff, so that continuous improvement can be guided by a detailed understanding of what works well.

To guide this transformational piece of work, health and organisational management researchers across Aston University will work with BCHC to develop a monitoring system to measure outcomes as each service and clinic is redesigned. This will combine qualitative methods, systems mapping and big data.

The system will measure patient experiences of care and help determine whether clinical outcomes are being achieved as services improve – such as reducing the likelihood of falls, preventing acute and critical illness, or better managing chronic conditions. It will also map the efficiency and flow of patients between hospital, community and home so that staff can rapidly intervene in the event of bottlenecks or delays.

For staff, the system will measure wellbeing, caseload and travel burdens as they move into community hubs across the city. These insights will enable the Birmingham and Solihull health and care services to operate an integrated community care system that is more sustainable for staff and can be continuously improved.

As other UK towns and cities look to redesign their health and care services in response to the UK government’s 10-year plan for the NHS, the Birmingham and Solihull model could offer a blueprint for others to learn from.

The KTP project will be led by researchers in Aston University’s Institute for Health and Neurodevelopment, Aston Business School and Aston Pharmacy School. They will bring expertise in developing and deploying data-driven methods for evaluating health services and community care projects, tried and tested through existing partnerships with the NHS.

Professor Rachel Shaw, associate director for researcher development (academic) at the Institute of Health and Neurodevelopment at Aston University, leads the KTP. She said: “Every NHS system is unique to the community it serves. We’re building an evidence-based way to monitor and guide the redesign of a health system that will be fit for the future and reusable for other organisations. Effective evaluation will support staff tasked with running NHS services across Birmingham and Solihull and empower them to continuously improve those services based on evidence. We want to see how staff as well as patients can benefit from care in the community, so that this programme can be a guiding light for other NHS systems across England.”

Dr Robbie Dedi, chief medical officer for BCHC, said: “Making it easier for citizens to access the care and support they need, when and where they need it, is the driving force behind the city’s transformation of health and care services. Our partnership with Aston University will be critical for enabling us to better identify and tackle health inequalities, so we can make services fairer and more accessible for everyone. The new monitoring systems we’re setting up together will guide us in what works, what needs to be improved and whether we’re managing our resources effectively. This will be the first major evaluation of how integrated care functions across Birmingham and Solihull.”

Knowledge Transfer Partnerships, funded by Innovate UK, are collaborative projects that bring together a business, an academic partner, and a qualified associate to deliver strategic innovation and business improvement. Aston University is a national leader in the programme, ranked joint-first in the UK for volume of active projects and first for overall project quality.

For further details about this KTP, visit www.aston.ac.uk/business/collaborate-with-us/knowledge-transfer-partnership/at-work/health-care-system.

Clinical fellowship opportunity – West Midlands Secure Data Environment

Birmingham Health Partners, in partnership with the West Midlands Secure Data Environment (WMSDE) and the Dexter platform team, is pleased to invite expressions of interest from clinicians in maternity and acute care to join our collaborative research and data innovation program.

About WMSDE and Dexter

WMSDE is an NHS platform that enables secure access to linked health and care data to approved users for research. WMSDE works in partnership with health and care organisations within the region to bring together disparate health information into linked multi-modal datasets for technology evaluation, clinical trials, translational studies, and real-world assessment of treatments and healthcare delivery systems. WMSDE is working in collaboration with Dexter, a clinical data enablement platform designed to extract, normalise and prepare health data into analysis-ready datasets. This significantly reduces the time required for data analysis and improves the accessibility of health and care data available for research to improve patient care.

The opportunity

We are seeking clinicians from maternity and acute care backgrounds with an interest in health informatics and real-world evidence to dedicate one day per week (0.2 FTE) to support the evaluation of the Dexter tool within the WMSDE health data environment. This role offers a unique opportunity to use new datasets and advanced automated data extraction to undertake research that improve patient care, while evaluating and improving the underlying technology.

Key responsibilities

Clinical guidance: provide expert clinical input for the development and validation of clinical phenotypes within the Dexter platform.

Research collaboration: develop and deliver high-priority research projects using the using DEXTER on the above datasets, supported by technical and academic colleagues in BHP.

Engagement: act as a bridge between frontline clinical needs and technical data engineering teams to ensure research outputs are clinically relevant and actionable.

Training and communication: contribute to the development of a clinical and academic community engaged in approved use of data to improve patient care.

Who should apply?

We welcome interest from senior healthcare professionals in maternity and acute care backgrounds (including but not limited to: consultants, specialty registrars, senior midwives, pharmacists, AHPs, healthcare scientists, clinical academics) who:

  • Have a strong interest in either medical informatics, data-driven research or quality improvement.
  • Possess a working knowledge of, or wish to be trained on, the development of clinical phenotypes using structured data (e.g., SNOMED CT, ICD-10, OPCS DM&D), and observational research
  • Can secure the support of their department for a 1-day-per-week commitment.

Why join us?

The collaboration places you at the heart of one of the UK’s leading Secure Data Environments and health partnerships. You will work alongside a multidisciplinary team of data scientists and researchers, gaining invaluable experience in automated health data research.

How to apply

Interested candidates should submit a short statement of interest (max 500 words) and a CV outlining:

  • Your clinical background and area of expertise
  • Your experience or interest in health data science and proposal of the broad areas of interest you would want to focus on
  • Confirmation of departmental support for the time commitment

Deadline for submission: Thursday 6 August 2026.

Contact for enquiries and applications: Cassie Conway

Healthcare professionals invited to apply for new regional research programme

Following the launch of the West Midlands Regional Account for Clinical Researchers (WMRACR), we’re pleased to announce that the programme is now accepting applications from doctors, nurses, dentists, midwives, therapists and pharmacists.

WMRACR is a partnership led by the University of Birmingham and funded by the Medical Research Council (MRC), working with Aston, Keele and Warwick universities to increase the number of clinical academics across the region.

These awards are designed to support talented postdoctoral clinical professionals and other healthcare staff to develop competitive research careers. Support includes:

  • Protected research time for ~12 months, delivered within your current role; typically at 50% time.
  • Mentorship and tailored training
  • Opportunities for interdisciplinary collaboration
  • Access to a strong regional research network

Applicants must be based within a West Midlands NHS Trust or University.

Application details
Further details, including eligibility and application guidance, are available on the WMRACR website.

The deadline for the first cohort is Friday September 11th. 

The WMRACR programme team will be hosting a series of webinars to answer any queries you may have on this. To register for one of these please contact the University of Birmingham ICAT team on icat@contacts.bham.ac.uk 

  • Wednesday 8th July 12:00-12:30
  • Wednesday 15th July 14:00-14:30
  • Tuesday 21st July 09:30-10:00

Drug to delay Type 1 Diabetes approved by NICE

Diabetes experts from across Birmingham Health Partners have welcomed the approval of teplizumab for use on the NHS, following an announcement by the National Institute for Health and Care Excellence (NICE).

The immunotherapy drug can delay the progression to symptomatic type 1 diabetes in people who are in stage 2 of the condition, and will now be available through the NHS for children over 8 years and adults with Stage 2 Type 1 Diabetes.

The NICE announcement follows work by academics and clinicians to improve the support available for children and young people who go onto develop type 1 diabetes. At BHP – via founding members the University of Birmingham, Birmingham Women’s and Children’s Hospitals and University Hospitals Birmingham NHS Foundation Trusts – research is ongoing through a screening programme which can help to identify young people at risk of the condition.

The ELSA (EarLy Surveillance for Autoimmune diabetes) study, led by Professor Parth Narendran, has seen thousands of young people screened for antibodies that act as markers for whether type 1 diabetes will develop later in life.

Today’s announcement recognises the crucial role that screening programmes, including ELSA, will have for identifying young people who will benefit from Teplizumab.

ELSA has also enabled patients to have early access to Teplizumab, with the first young person in the UK, 14-year-old Sam from Kings Norton, receiving the drug at Birmingham Children’s Hospital under the care of Dr Renuka Dias and her specialist team at the Clinical Research Facility. Now, with the approval for funded use on the NHS it is estimated that around 1,100 people could be eligible for teplizumab in the first year-based data provided from the ELSA study.

Parth Narendran, Professor of Diabetes Medicine at the University of Birmingham said: “Today’s NICE recommendation for teplizumab marks a significant milestone in the UK for people at the very earliest stages of type 1 diabetes.

“As the first disease-modifying therapy shown to delay progression to clinical, insulin-requiring type 1 diabetes, teplizumab has the potential to transform the treatment paradigm from reacting to disease onset to intervening earlier in the disease process. This means that patients identified early, for example through the ELSA study led by the University of Birmingham, will have benefit from treatment that can give valuable additional years free from the daily burden of managing type 1 diabetes.

“This decision will go a long way to help the development of screening, monitoring and prevention pathways that will underpin the future of type 1 diabetes care.”

Type 1 diabetes is an autoimmune condition that causes the body to attack and destroy insulin-producing cells in the pancreas. Without insulin, blood glucose levels rise dangerously, and, without treatment, death. Diagnosis often comes suddenly and in crisis – one in four children in the UK are diagnosed in diabetic ketoacidosis (DKA), a life-threatening emergency caused by extremely high blood glucose levels and requires emergency treatment in hospital.

Teplizumab targets the immune system’s attack on insulin-producing beta cells in the pancreas. By modulating the immune response, it can delay the onset of clinical type 1 diabetes in people who are in stage 2.

Clinical trials have shown that a single course of teplizumab, which is administered in hospital daily for 14 days, can halve the progression rates to symptomatic type 1 diabetes.

Following today’s announcement, NHS will need to develop new testing and treatment pathways to make teplizumab available in practice.

Work is already under way to help build this infrastructure. The ELSA study, which is  co-funded by Diabetes UK and Breakthrough T1D, demonstrated what childhood screening for type 1 diabetes might look like in the real world.

A second phase, ELSA 2, was launched with £1.5 million in funding and has expanded screening to all children aged 2 to 17 across the UK and aiming to recruit a further 30,000 children.

ELSA 2 will also establish new NHS Early-Stage Type 1 Diabetes Clinics, providing families with clinical and psychological support and creating a clear pathway from screening through to diagnosis, monitoring and treatment.

Dr Renuka Dias, a Consultant Paediatric Endocrinologist working at Birmingham Women and Children’s Hospital and is an Honorary Associate Clinical Professor at the University of Birmingham and the Lead Paediatrician for the ELSA study.

Dr Dias said: “The approval of teplizumab by NICE offers people with early-stage Type 1 Diabetes to delay the need for insulin potentially for several years and represents a genuine step-change in how we think about the management of this relentless condition and hope that in time we can move closer to managing Type 1 diabetes without insulin as the first-line therapy.”

The announcement that teplizumab will be available on the NHS will give young people and adults more time to prepare for living with type 1 diabetes, with trial data suggesting that the drug can delay the onset of symptomatic diabetes by an average of 2.5 years.

As well as teplizumab, academics at the University of Birmingham are researching other ways to preserve the cells that produce insulin in the pancreas, and which are lost in type 1 diabetes.

Colin Dayan, Professor of Clinical Diabetes and Metabolism is collaborating with colleagues across the UK in the Type 1 Diabetes Immunotherapy Consortium to conduct clinical trials in adults and children with new-onset type 1 diabetes and develop new approaches to beta cell preservation and ultimately aim to find ways to manage type 1 diabetes without the need for insulin dependency.

Professor Dayan said: “This is such an exciting moment – it is the first step towards treating type 1 diabetes without insulin. Teplizumab delays the need for insulin by more than 2 years. Many other drugs have also shown promise in slowing the damage to insulin making cells by the immune system. As we pick up more cases early by screening and combine treatments to retain the body’s insulin making cells for longer and longer, we can foresee the day that insulin treatment in children becomes a thing of the past.”